Tumors affecting the central nervous system (CNS), either primary or secondary, are highly prevalent and represent an unmet medical need. Prognosis of these tumors remains poor, mostly due to the low intrinsic chemo/radio-sensitivity of tumor cells, a meagerly known role of the microenvironment and the poor CNS bioavailability of most used anti-cancer agents. The BBTB is the main obstacle for anticancer drugs to achieve therapeutic concentrations in the tumor tissues. During the last decades, many efforts have been devoted to the identification of modalities allowing to increase drug delivery into brain tumors. Until recently, success has been modest, as few of these approaches reached clinical testing and even less gained regulatory approval.

They discovered that removing PLD3 from neurons using gene therapy resulted in a significant decrease in axonal swelling.

A study on Alzheimer’s published recently by Yale University is quite attention-grabbing. Because the disease’s crippling symptoms could be brought on by swelling in the brain brought on by amyloid plaques, say the experts.

One of the main features of Alzheimer’s is the formation of amyloid plaques. Researchers have been trying to shrink these plaques in their researchers for years. In addition, Yale researchers have found that swelling caused by a byproduct of these plaques may be the cause of the disease’s debilitating symptoms.

Gravity could be a leading cause of irritable bowel syndrome, along with increased serotonin levels and changes in the gut microbiome.

Approximately 20 to 40 percent of all visits to gastroenterologists are due to irritable bowel syndrome (IBS) symptoms. The common disorder affects between 25 and 45 million people in the United States and up to ten percent of the world’s population, yet experts aren’t sure of how or why it develops.

However, there is no dearth of theories. While one explains that IBS is a gut-brain disorder, another theory states that IBS is caused by abnormalities in the gut microbiome.